Suven制药公司从美国NJ Bio公司获得56%的644M美元,以扩大ADC市场。 Suven Pharmaceuticals acquires 56% of US-based NJ Bio for $64.4M to expand in ADC market.

印度制药公司苏文制药公司以6440万美元的价格收购了NJ Bio Inc的56%股权,这是一家专门从事抗体药物联合体 (ADC) 的美国合同开发和制造组织. Suven Pharmaceuticals, an Indian pharmaceutical company, is acquiring a 56% stake in NJ Bio Inc, a US-based contract development and manufacturing organization specializing in antibody-drug conjugates (ADCs), for $64.4 million. 这次收购定于2024年12月结束,目的是加强Suven在迅速增长的ADC市场中的地位,该市场价值27亿美元,预计将每年增长25%以上。 The acquisition, set to close by December 2024, aims to strengthen Suven's position in the rapidly growing ADC market, valued at $2.7 billion and projected to grow over 25% annually. NJ Bio是由ADC科学家Naresh Jain创办的,预计2024年的收入将达到3 200万美元。 NJ Bio, founded by ADC scientist Naresh Jain, is expected to record revenues of $32 million in 2024.